Basilea Pharmaceutica AG (0QNA.L)

41.40 +0.20 (+0.50%) As of 01:41PM BST. Market open.

Basilea Pharmaceutica AG

Hegenheimermattweg 167b
Allschwil 4123
Switzerland
41 61 606 11 11
https://www.basilea.com

Sector(s): 
Industry: 
Full-time employees: 147

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Veitch	Chief Executive Officer	1.13M	N/A	1965
Mr. Adesh Kaul	Chief Financial Officer	N/A	N/A	1974
Dr. Gerrit Hauck Ph.D.	Chief Technology Officer	N/A	N/A	1964
Dr. Laurenz Kellenberger Ph.D.	Chief Scientific Officer	N/A	N/A	1967
Dr. Marc Engelhardt M.D.	Chief Medical Officer	N/A	N/A	1964
Dr. Peer Nils Schroder	Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Damian Heller	General Counsel & Corporate Secretary	N/A	N/A	1966
Mr. Andreas Kumin	Head of Corporate Development	N/A	N/A	N/A
Ms. Ursula Eberhardt	Head of Global Human Resources	N/A	N/A	1962
Mr. Mark Jones	Head of Project Management & Preclinical Development	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Corporate governance

Basilea Pharmaceutica AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.